Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Peginterferon Lambda  COVID-19 treatment studies for Peg.. Lambda  C19 studies: Peg.. Lambda  Peg.. Lambda   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 72% Improvement Relative Risk Hospitalization 43% Hospitalization/ER 51% c19early.com/il Eiger BioPharmaceuticals et al. NCT04727424 Peg.. Lambda RCT EARLY Favors peg.. lambda Favors control
Eiger BioPharmaceuticals, 1,936 patient peginterferon lambda early treatment RCT: 72% lower mortality [p=0.38], 43% lower hospitalization [p=0.04], and 51% fewer combined hospitalization/ER visits [p=0.002] https://c19p.org/eigeril
copied to clipboard
Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
Eiger BioPharmaceuticals (Preprint)
17 Mar 2022    Source   PDF   Share   Tweet
High-risk outpatient RCT with 916 peginterferon lambda patients and 1,020 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection. NCT04727424.
For more discussion see [twitter.com].
risk of death, 72.2% lower, RR 0.28, p = 0.38, treatment 1 of 916 (0.1%), control 4 of 1,020 (0.4%), NNT 353.
risk of hospitalization, 43.0% lower, RR 0.57, p = 0.04, treatment 21 of 916 (2.3%), control 41 of 1,020 (4.0%), NNT 58.
risk of hospitalization/ER, 51.2% lower, RR 0.49, p = 0.002, treatment 25 of 916 (2.7%), control 57 of 1,020 (5.6%), NNT 35.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Eiger BioPharmaceuticals et al., 3/17/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, South America, preprint, 1 author, trial NCT04727424.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit